<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415285</url>
  </required_header>
  <id_info>
    <org_study_id>EU822-03</org_study_id>
    <nct_id>NCT00415285</nct_id>
  </id_info>
  <brief_title>Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia Center for Oncology Research &amp; Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgia Center for Oncology Research &amp; Education</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify new chemotherapy treatment regimens with better
      response rates and to find out if the combination of docetaxel and capecitabine can shrink
      the size of breast tumors and preserve the breast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to identify new chemotherapy treatment regimens with better
      response rates and to find out if the combination of docetaxel and capecitabine can shrink
      the size of breast tumors and preserve the breast.

      Induction chemotherapy offers the possibility of less surgery and determines tumor
      sensitivity in vivo. Previous trials have demonstrated that complete pathologic response in
      the breast at surgery corresponds with improved outcome. Additionally, we will correlate
      specific molecular markers in the breast tumors before and after chemotherapy, with response
      to treatment.

      Expression of these molecular markets may be used in the future to predict the likelihood of
      response to chemotherapy given post-operatively.

      Approximately 100 patients will participate at Emory Winship Cancer Institute and Emory
      Crawford W. Long Hospital and Grady Health System in Atlanta, Georgia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel/Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast carcinoma.

          -  Early stage breast cancer (stage 1, 2, 3).

          -  No evidence of disease outside the breast or chest wall, except ipsilateral axillary
             lymph nodes.

          -  18 years of age or older.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.

        Exclusion Criteria:

          -  Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast
             cancer.

          -  Major surgery within 28 days of study entry.

          -  Evidence of CNS metastases.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth O'Regan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rita Johnson</last_name>
    <phone>404-778-7777</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Crawford Long Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.georgiacore.org</url>
    <description>Georgia Center for Oncology Research and Education</description>
  </link>
  <link>
    <url>http://www.winshipcancerinstitute.org/</url>
    <description>Winship Cancer Institute</description>
  </link>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>February 12, 2007</last_update_submitted>
  <last_update_submitted_qc>February 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2007</last_update_posted>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Early-Stage</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

